William Blair & Company
AKBA icon

William Blair & Company’s Akebia Therapeutics AKBA Stock Holding History

William Blair & Company’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Buy
+16,146
New +$19.2K ﹤0.01% 1864
2022
Q1 		– Sell
-16,599
Closed -$38K – 1909
2021
Q4 		$38K Sell
16,599
-6,306
-28% -$17.2K ﹤0.01% 1798
2021
Q3 		$66K Sell
22,905
-4,058
-15% -$11.6K ﹤0.01% 1655
2021
Q2 		$102K Hold
26,963
– – ﹤0.01% 1610
2021
Q1 		$91K Buy
26,963
+1,411
+6% +$5.08K ﹤0.01% 1605
2020
Q4 		$72K Sell
25,552
-47,250
-65% -$138K ﹤0.01% 1581
2020
Q3 		$183K Buy
72,802
+9,252
+15% +$81.2K ﹤0.01% 1332
2020
Q2 		$863K Sell
63,550
-1,243
-2% -$12.9K ﹤0.01% 758
2020
Q1 		$491K Hold
64,793
– – ﹤0.01% 873
2019
Q4 		$409K Sell
64,793
-8,608
-12% -$40.9K ﹤0.01% 1063
2019
Q3 		$288K Sell
73,401
-2,000
-3% -$8.57K ﹤0.01% 1133
2019
Q2 		$365K Hold
75,401
– – ﹤0.01% 1087
2019
Q1 		$618K Buy
75,401
+5,826
+8% +$40K ﹤0.01% 895
2018
Q4 		$385K Buy
+69,575
New +$544K ﹤0.01% 993

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

William Blair & Company's AKBA Position: Q2 2026 in Review

William Blair & Company opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 16,146 shares worth $18.4K. The stake represents ﹤0.01% of the portfolio and ranks #1864 among its holdings. This is a return to the name: William Blair & Company previously reported a position in AKBA as recently as Q4 2021.

William Blair & Company first reported a position in AKBA in Q4 2018 and has held it in 14 quarters since. The position peaked at $863K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • William Blair & Company held 16,146 shares of Akebia Therapeutics worth $18.4K as of Q2 2026.
  • Akebia Therapeutics was a new William Blair & Company position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1864 holding.
  • William Blair & Company first reported a position in Akebia Therapeutics in Q4 2018 and has held it in 14 quarters since.
  • William Blair & Company's Akebia Therapeutics position peaked at $863K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.